Literature DB >> 22627890

Assessment of an asymmetrical coating stent with sirolimus released from ablumial matrix in porcine model.

Li Shen1, Yizhe Wu, Feng Zhang, Lingxiang Wu, Chao Dong, Yongxing Gao, Aijun Sun, Yunzeng Zou, Juying Qian, Jianguo Sun, Wei Zhong, Junbo Ge.   

Abstract

BACKGROUND: Delayed endothelialization contributes to stent thrombosis of current drug-eluting stents. The asymmetrical coating technique provides an anti-proliferative effect abluminally without affecting luminal endothelialization. Layer-by-layer self-assembled chitosan/heparin (C/H LBL) has been proved to promote re-endothelialization. A novel stent system, C/H LBL coated luminally and sirolimus released abluminally (C/H LBL-SES), was fabricated.
METHODS: Bare metal stents (BMS), traditionally circumferential sirolimus-eluting stents (SES), and C/H LBL-SES were implanted into porcine coronary arteries. At the 7, 14 and 28 days follow-up (FU), angiography, intravascular ultrasound (IVUS), vasomotor function induced by acetylcholine (Ach), scanning-electron microscopy and histopathology were performed. Remodeling index (RI) was based on IVUS and defined as cross-sectional area (CSA) of vessel at in-stent segment divided by CSA of reference vessel and expressed as a percentage with a normal range from 0.95 to 1.05.
RESULTS: Thirty-eight mini pigs were enrolled and 74 stents (BMS = 23, C/H LBL = 28, SES = 23) were implanted in this study. At 28 days after implantation, the diameter stenosis of C/H LBL-SES by quantitative coronary angiography was 18.8 ± 2.5 %, the area stenosis by histomorphometry was 24.2 ± 2.9 %, which were comparable to that of SES and superior to BMS. At 14 days, re-endothelialization of C/H LBL-SES was almost completed, while only about 50 % of surface of SES was covered by endothelium. At 7, 14 and 28 days FU, although C/H LBL-SES suffered a greater vasoconstriction induced by Ach infusion than BMS (P < 0.05), it behaved better than SES (P < 0.01). No sign of stent malapposition was detected, while RI was within the normal range by IVUS. No acute or subacute thrombotic events occurred in all three groups.
CONCLUSIONS: The asymmetrically designed C/H LBL-SES successfully inhibited neointima hyperplasia, while diminishing vasoconstriction after Ach-stress. Endothelialization of C/H LBL-SES was less affected compared with traditionally circumferentially coated SES.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22627890     DOI: 10.1007/s00392-012-0476-7

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  24 in total

1.  Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function.

Authors:  Hugues Jeanmart; Olivier Malo; Michel Carrier; Caroline Nickner; Nathalie Desjardins; Louis P Perrault
Journal:  J Heart Lung Transplant       Date:  2002-09       Impact factor: 10.247

2.  Emerging thrombotic effects of drug eluting stents.

Authors:  Ninian N Lang; David E Newby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-02       Impact factor: 8.311

3.  The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system.

Authors:  Sheng Meng; Zongjun Liu; Li Shen; Zhang Guo; Laisheng L Chou; Wei Zhong; Qiangguo Du; Junbo Ge
Journal:  Biomaterials       Date:  2009-01-24       Impact factor: 12.479

4.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.

Authors:  Michael Joner; Aloke V Finn; Andrew Farb; Erik K Mont; Frank D Kolodgie; Elena Ladich; Robert Kutys; Kristi Skorija; Herman K Gold; Renu Virmani
Journal:  J Am Coll Cardiol       Date:  2006-05-05       Impact factor: 24.094

5.  Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials.

Authors:  Antoinette de Waha; Salvatore Cassese; Duk-Woo Park; Francesco Burzotta; Robert A Byrne; Tomohisa Tada; Lamin A King; Seung-Jung Park; Albert Schömig; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2012-03-16       Impact factor: 5.460

6.  A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent.

Authors:  Eberhard Grube; Joachim Schofer; Karl E Hauptmann; Georg Nickenig; Nicholas Curzen; Dominic J Allocco; Keith D Dawkins
Journal:  JACC Cardiovasc Interv       Date:  2010-04       Impact factor: 11.195

7.  Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization.

Authors:  Gaku Nakazawa; Juan F Granada; Carlos L Alviar; Armando Tellez; Greg L Kaluza; Margaret Yoklavich Guilhermier; Sherry Parker; Stephen M Rowland; Frank D Kolodgie; Martin B Leon; Renu Virmani
Journal:  JACC Cardiovasc Interv       Date:  2010-01       Impact factor: 11.195

8.  Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes.

Authors:  Dimytri A Siqueira; Alexandre A Abizaid; Jose de Ribamar Costa; Fausto Feres; Luiz A Mattos; Rodolfo Staico; Andrea A Abizaid; Luiz F Tanajura; Aurea Chaves; Marinella Centemero; Amanda G M R Sousa; J Eduardo M R Sousa
Journal:  Eur Heart J       Date:  2007-05-03       Impact factor: 29.983

9.  Endothelial cell recovery between comparator polymer-based drug-eluting stents.

Authors:  Michael Joner; Gaku Nakazawa; Aloke V Finn; Shawn Chin Quee; Leslie Coleman; Eduardo Acampado; Patricia S Wilson; Kristi Skorija; Qi Cheng; Xin Xu; Herman K Gold; Frank D Kolodgie; Renu Virmani
Journal:  J Am Coll Cardiol       Date:  2008-07-29       Impact factor: 24.094

10.  Abnormal vasomotor function of porcine coronary arteries distal to sirolimus-eluting stents.

Authors:  Jinsheng Li; Refat Jabara; Lakshmana Pendyala; Yoritaka Otsuka; Toshiro Shinke; Dongming Hou; Keith Robinson; Nicolas Chronos
Journal:  JACC Cardiovasc Interv       Date:  2008-06       Impact factor: 11.195

View more
  4 in total

1.  Safety and efficacy of different stent types for the endovascular therapy of extracranial vertebral artery disease.

Authors:  Nicolas Langwieser; Sascha Prothmann; Dominique Buyer; Holger Poppert; Tibor Schuster; Massimiliano Fusaro; Petra Barthel; Hans-Ulrich Haase; Karl-Ludwig Laugwitz; Claus Zimmer; Tareq Ibrahim
Journal:  Clin Res Cardiol       Date:  2013-12-28       Impact factor: 5.460

2.  First in vitro and in vivo results of an anti-human CD133-antibody coated coronary stent in the porcine model.

Authors:  Alexander Sedaghat; Jan-Malte Sinning; Kathrin Paul; Gregor Kirfel; Georg Nickenig; Nikos Werner
Journal:  Clin Res Cardiol       Date:  2013-02-10       Impact factor: 5.460

Review 3.  Spatio-Temporal Control of LbL Films for Biomedical Applications: From 2D to 3D.

Authors:  Claire Monge; Jorge Almodóvar; Thomas Boudou; Catherine Picart
Journal:  Adv Healthc Mater       Date:  2015-01-27       Impact factor: 9.933

4.  Phenotypic transformation of smooth muscle cells from porcine coronary arteries is associated with connexin 43.

Authors:  Xumin Zhang; Xiaodong Wang; Xiaohui Zhou; Xiaoye Ma; Yian Yao; Xuebo Liu
Journal:  Mol Med Rep       Date:  2016-05-13       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.